Because postoperative pain is to a large extent an inflammatory phenomenon, administration of systemic local anesthetics, which have inflammatory modulatory properties, 4 could significantly reduce pain and therefore allow more rapid discharge. 5 Lidocaine has an excellent safety record when administered by low-dose infusion. [5] [6] [7] However, whereas decreased hospital stay after inpatient surgery has been demonstrated, the effect of intraoperative and early postoperative lidocaine infusion on duration of stay after ambulatory surgery is not known. Although it seems logical that decreased pain would allow earlier discharge, it is conceivable that, e.g., mild sedating effects of lidocaine could prolong postanesthesia care unit (PACU) admission and interfere with discharge.
We hypothesized that lidocaine, when administered systemically during the operative and early postoperative period, would decrease length of PACU stay (primary outcome measure). Secondary outcome measures were postoperative pain, opioid requirements, and postoperative nausea and vomiting.
METHODS
After IRB approval, informed consent was obtained from patients 18 -75 yr of age (ASA physical status I-III) presenting for outpatient surgery under general anesthesia between August 2004 and August 2006.
Participants were assigned in a double-blind 1:1 ratio using a computer-generated randomization list to receive either a lidocaine or saline placebo infusion. At induction, all patients received 1.5 mg/kg of lidocaine by slow IV push. The lidocaine infusion (2 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 or equivalent volume of saline as placebo) was started immediately after induction of anesthesia and continued until 1 h after arrival in the PACU. Anesthetic management during surgery was standardized for opioid use (fentanyl as required and morphine up to 0.15 mg/kg), ketorolac (up to 30 mg IV after hemostasis was obtained if not contraindicated), and prophylaxis for postoperative nausea and/or vomiting (dexamethasone up to 0.1 mg/kg). In the PACU, pain was assessed at rest by a visual analog scale every 15 min and treated with either fentanyl (0.5-1 g/kg) or morphine (0.01-0.02 mg/kg) when pain was more than 3 on a visual analog scale of 0 -10 (0 ϭ no pain, 10 ϭ more pain imaginable). Nausea was assessed at 15-min intervals and treated with ondansetron or if persistent with promethazine or diphenhydramine. Discharge readiness was assessed by the PACU nurse using the modified Aldrete score every 15 min. 8 Patients were given a journal to record their analgesic use and level of pain and nausea the first 24 h after discharge. These data were obtained by a follow-up telephone call.
Twenty-five patients per group were needed to show a 30% reduction in our primary end point, time to the PACU discharge readiness (based on standard deviation of 50 min [estimated by chart audit]; 1 Ϫ ␤ ϭ 0.8, ␣ ϭ 0.05). This would translate to a reduction in discharge readiness from 120 min to 84 min, i.e., somewhat more than half an hour. Based on an expected withdrawal rate of 20%, 67 patients were enrolled in the trial. The primary end point was obtained by subtracting the time of arrival in the PACU from the time that patient discharge readiness was attained using the modified Aldrete score. PACU stay durations follow a 2-parameter lognormal distribution (P Ͼ 0.7). 9 We compared the groups by lognormal transformation followed by calculation of the 95% confidence interval using the referenced generalized pivotal approach. 10 Postoperative opioid requirements were calculated for each patient by converting opioids to morphine (mg) IV equivalents (Table 1) , and the sample means from treatment and control groups were compared using a 2-tailed t-test for independent samples. The presence of nausea and vomiting in each group was analyzed using 2 
RESULTS
Baseline demographic data as well as type and duration of surgical procedures were comparable between the 2 groups (Table 2 ). Patients in the lidocaine group received 517 Ϯ 203 mg lidocaine during the infusion.
There was no difference in the primary outcome measure, length of PACU stay, between the groups (133 Ϯ 58 min vs 135 Ϯ 55 min; P ϭ 0.89). The 95% confidence interval after lognormal transformation was Ϫ31 to 39 min.
Intraoperative opioid use (in morphine IV equivalent doses [MEQ]) was reduced by approximately 30% in the lidocaine group (20.52 Ϯ 10.55 vs 30.15 Ϯ 16.59; P ϭ 0.017), approximately 50% in the PACU (MEQ: 8.72 Ϯ 9.54 vs 15.93 Ϯ 10.95; P ϭ 0.015), and by approximately 40% during the total study period (operating room, PACU, and up to 24 h after discharge) (MEQ: 36.08 Ϯ 17.13 vs 59.53 Ϯ 18.59; P ϭ 0.002). However, the use of analgesics during the first 24 h after hospital discharge was not significantly different between the groups (MEQ: 9.17 Ϯ 9.14 vs 10.19 Ϯ 10.45; P ϭ 0.76) (Fig. 1) . In the PACU, patients in the lidocaine group reported less pain at rest (VAS: 3.1 Ϯ 2.04 vs 4.5 Ϯ 2.9; P ϭ 0.043) (Fig. 2) . Twenty-four hours later, there were no differences in average pain scores (rest and activity) (VAS: 4.1 Ϯ 1.8 vs 4.0 Ϯ 2.4; P ϭ 0.97). No statistical differences were found for nausea (10 vs 13; P ϭ 0.825) and vomiting (4 vs 5; P ϭ 0.733).
There were no serious adverse events recorded. One patient reported dizziness and visual disturbance at the end of the infusion (lidocaine plasma level 2.4 g/mL).
DISCUSSION
Several previous studies have examined the effect of IV lidocaine on recovery after surgery. Martin et al. 11 reported that a low-dose perioperative IV lidocaine after total hip surgery offers no beneficial effect on postoperative analgesia and does not modify pressure and tactile pain thresholds. In contrast, a metaanalysis of 8 randomized, controlled, clinical trials in patients undergoing abdominal surgery showed that continuous perioperative IV lidocaine administration reduces the duration of postoperative ileus, pain, nausea, and vomiting and shortens hospital stay. 12 However, none of these studies focused on surgery in the ambulatory setting.
To make the study clinically relevant, we accepted a relatively inhomogeneous study population, reduced standardization of anesthetic (without measurement of minimum alveolar concentration hours) and analgesic regimen, and lack of certain outcome data (recovery of gastrointestinal function and resumption of normal activities of daily living). Still, we found an opioid-sparing effect in the perioperative and early postoperative period. These effects did not affect recovery time by more than half an hour. The opioid-sparing effect of IV lidocaine did not affect the incidence of nausea and vomiting in our study population. The nonhomogeneous study population and the administration of a lidocaine bolus before the administration of the study medication in both groups may have minimized possible differences between the 2 study groups. However, because it is safe, inexpensive, and does not require additional monitoring to that routinely provided in the PACU setting, lidocaine offers a potential therapeutic approach for perioperative analgesia in the outpatient setting.
